SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Rabkin JM, de La Melena V, Orloff SL, Corless CL, Rosen HR, Olyaei AJ. Late mortality after orthotopic liver transplantation. Am J Surg 2991; 181: 475479.
  • 2
    Dikow R, Degenhard M, Kraus T, Sauer P, Schemmer P, Uhl W, et al. Blood pressure profile and treatment quality in liver allograft recipients—benefit of tacrolimus versus cyclosporine. Transplant Proc 2004; 36: 15121515.
  • 3
    Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE. Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl 2000; 6: 521530.
  • 4
    Canzanello VJ, Textor SC, Taler SJ, Schwartz LL, Porayko MK, Wiesner RH, et al. Late hypertension following liver transplantation: comparison of cyclosporine A and tacrolimus. Liver Transpl Surg 1998; 4: 328334.
  • 5
    Gonwa TA. Hypertension and renal dysfunction in long term liver transplant recipient. Liver Transpl 2001; 7( suppl 11): S22S26.
  • 6
    Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69: 11821193.
  • 7
    Calo L, Semplicini A, Davis PA, Bonvicini P, Cantaro S, Rigotti P, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved? Transpl Int 2000; 13: S413S418.
  • 8
    Calo L, Giacon B, Davis PA, Pagnin E, Piccin A, Riegler P, et al. Oxidative stress and TGF β in kidney-transplant patients with cyclosporine-induced hypertension. Effects of carvedilol and nifedipine. Clin Nephrol 2002; 58: 103110.
  • 9
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 12061252.
  • 10
    Erdine S, Ari O, Zanchetti A, Cifkova R, Fagard R, Kjeldsen S, et al. ESH-ESC guidelines for the management of hypertension. Herz 2006; 31: 331338.
  • 11
    O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23: 697701.
  • 12
    Textor SC. De novo hypertension after liver transplantation. Hypertension 1993; 22: 257267.
  • 13
    Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 1989; 321: 10141022.
  • 14
    Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS. The sodium retaining effects of cyclosporine. Kidney Int 1992; 41: 15991605.
  • 15
    Canzanello VJ, Textor SC, Taler SJ, Wilson DJ, Schwartz L, Wiesner RH, et al. Renal sodium handling with cyclosporine A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol 1995; 5: 19101917.
  • 16
    Woo KS, Pun CO. Long acting nifedipine versus metoprolol as monotherapy for essential hypertension. A randomized, controlled cross-over-study. West J Med 1990; 152: 149152.
  • 17
    MacLean D, Ramsay LE, Richardson PJ. Enalaprin and nifedipine in the treatment of mild to moderate essential hypertension. A 6 month comparison. Br J Clin Pharmacol 1990; 30: 203211.
  • 18
    Toal CB, Mhon WA, Barves C, Burelle D. Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalt Canadian Trial (EXACT). Clin Ther 1997; 19: 924935.
  • 19
    Kronig B, Widmann L, Staiger C, Machwirth M, Stienen U, Hennig M. Blood pressure lowering effect of carvedilol vs nifedipine in geriatric hypertensives. Eur J Clin Pharmacol 1990; 38( suppl 2): S167S170.
  • 20
    McTavish D, Campoli-Richards D, Sorkin EM. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1993; 45: 232258.
  • 21
    Plavnik FL, Freitas AF, Portela JE, Dantas M, Spritzer T, Kohlmann NE, et al. Use of carvedilol compared to nifedipine in the treatment of mild and moderate essential arterial hypertension. Arq Bras Cardiol 1994; 63: 405408.
  • 22
    Radevski IV, Valtchanova SP, Candy GP, Tshele EF, Sareli P. Comparison of acebutol with and without hydrochlorothiazide versus carvedilol with and without hydrochlorothiazide in black patients with mild to moderate systemic hypertension. Am J Cardiol 1999; 84: 7075.
  • 23
    Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC Jr, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 13321339.
  • 24
    Salvetti A, Innocenti PF, Iardella M, Pambianco F, Saba GC, Rossetti M, et al. Captopril and nifedipine interactions in the treatment of essential hypertensives: a cross-over study. J Hypertens 1987; 5( suppl 4): S139S142.
  • 25
    Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combinations therapy of angiotensine-converting enzyme inhibitor (benapril) with calcium antagonist (either nifedipine or amlodipine) versus high dose of calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86: 11821187.
  • 26
    Gustafsson D. Microvascular mechanisms involved in calcium antagonists oedema formation. J Cardiovasc Pharmacol 1987; 10( suppl 1): S121S131.
  • 27
    van Hamersvelt HW, Kloke HJ, de Jong DJ, Koene RA, Huysmans FT. Oedema formation with the vasodilatators nifedipine and diaxozide: direct local effect or sodium retention? Hypertension 1996; 14: 10411045.
  • 28
    Fernandez-Varo G, Ros J, Morales-Ruiz M, Cejudo-Martin P, Arroyo V, Sole M, et al. Nitric oxide synthase 3-dependent vascular remodelling and circulatory dysfunction in cirrhosis. Am J Pathol 2003; 162: 19851993.
  • 29
    Frampton JE, Peters DH. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995; 49: 440465.
  • 30
    Bainbridge AD, Macfadyen RJ, Stark S, Lees KR, Reid JL. The anti-hypertensive efficacy and tolerability of a low dose combination of ramipril and felodipine ER in mild to moderate essential hypertension. Br J Clin Pharm 1993; 36: 323330.
  • 31
    Dupont AG. Effects of carvedilol on renal function. J Clin Pharmacol 1990; 38( suppl 2): S96S100.
  • 32
    Stornello M, Di Rao G, Iachello M, Pisani R, Scapellato L, Pedrinelli R, et al. Haemodynamic and humoral interactions between captopril and nifedipine. Hypertension 1983; 5( suppl 2): S154S156.
  • 33
    Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium channel blockade (nitrendipine) in combination with ACE inhibitors (captopril) in the treatment of mild to moderate hypertension. Cardiovasc Drugs Ther 1989; 3( suppl): 319325.
  • 34
    Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC, for the Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol 1997; 79: 431435.
  • 35
    Mancia G, Omboni S, Grassi G. Combination treatment in hypertension: the VeraTran study. Am J Hypertens 1997; 10: S153S158.
  • 36
    Kaijser M, Johnsson C, Zezina L, Backman U, Dimeny E, Fellstrom B. Elevation of cyclosporine A blood levels during carvedilol treatment in renal transplant patients. Clin Transplant 1997; 11: 577581.
  • 37
    Bader FM, Hagan ME, Crompton JA, Gilbert EM. The effect of beta-blocker on cyclosporine level in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 21442147.